Abstract
Androgen deprivation therapy (ADT) is a cornerstone of the systemic treatment of advanced prostate cancer. It is indicated mainly in case of metastatic or locally advanced disease and in combination with radiotherapy in case of medium or high-risk prostate cancer.
Instead of bilateral orchiectomy, we currently choose luteinizing hormone-releasing hormone (LHRH) analogues or degarelix. A choice of medication and a form of administration depends on an experience of a physician, condition and cooperation of a patient and his comorbidities.
Long-acting, i.e. semi-annual regimens have a significant effect on a patient's comfort and logistics of a specific medical facility. Achieving effective castration and the lowest possible prostate specific antigen levels significantly affects a patient's prognosis.
It is necessary to consult a patient in advance about the side effects of ADT and instruct him on necessary measures.